Li Yanda, Zhang Zhenpeng, Xiong Xingjiang, Cho William C, Hu Dan, Gao Yonghong, Shang Hongcai, Xing Yanwei
Department of Cardiology, Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China.
Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
Front Physiol. 2017 Nov 27;8:952. doi: 10.3389/fphys.2017.00952. eCollection 2017.
Invasive coronary revascularization has been shown to improve prognoses in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), but the optimal timing of intervention remains unclear. This meta-analysis is to evaluate the outcomes in immediate (<2 h), early (<24 h), and delayed invasive group and find out which is the optimal timing of intervention in NSTE-ACS patients. Studies were identified through electronic literature search of Medline, PubMed Central, Embase, the Cochrane Library, and CNKI. Data were extracted for populations, interventions, outcomes, and risk of bias. All-cause mortality was the pre-specified primary end point. The longest follow-up available in each study was chosen. The odds ratio (OR) with 95% CI was the effect measure. The fixed or random effect pooled measure was selected based on the heterogeneity test among studies. In the comparison between early and delayed intervention, we found that early intervention led to a statistical significant decrease in mortality rate ( = 6,624; OR 0.78, 95% CI: 0.61-0.99) and refractory ischemia ( = 6,127; OR 0.50, 95% CI: 0.40-0.62) and a non-significant decrease in myocardial infarction (MI), major bleeding and revascularization. In the analysis comparing immediate and delayed invasive approach, we found that immediate intervention significantly reduced major bleeding ( = 1,217; OR 0.46, 95% CI: 0.23-0.93) but led to a non-significant decrease in mortality rate, refractory ischemia and revascularization and a non-significant increase in MI. In conclusion, early invasive strategy may lead to a lower mortality rate and reduce the risk of refractory ischemia, while immediate invasive therapy shows a benefit in reducing the risk of major bleeding.
有创冠状动脉血运重建已被证明可改善非ST段抬高型急性冠状动脉综合征(NSTE-ACS)患者的预后,但最佳干预时机仍不明确。本荟萃分析旨在评估即刻(<2小时)、早期(<24小时)和延迟有创治疗组的结局,并找出NSTE-ACS患者的最佳干预时机。通过对Medline、PubMed Central、Embase、Cochrane图书馆和中国知网进行电子文献检索来确定研究。提取有关人群、干预措施、结局和偏倚风险的数据。全因死亡率是预先设定的主要终点。选择每项研究中可用的最长随访时间。效应量采用95%置信区间的比值比(OR)。根据研究间的异质性检验选择固定效应或随机效应合并测量方法。在早期与延迟干预的比较中,我们发现早期干预导致死亡率(n = 6,624;OR 0.78,95%CI:0.61-0.99)和难治性缺血(n = 6,127;OR 0.50,95%CI:0.40-0.62)有统计学显著降低,心肌梗死(MI)、大出血和血运重建有非显著降低。在比较即刻与延迟有创治疗方法的分析中,我们发现即刻干预显著降低了大出血(n = 1,217;OR 0.46,95%CI:0.23-0.93),但导致死亡率、难治性缺血和血运重建有非显著降低,MI有非显著增加。总之,早期有创策略可能导致较低的死亡率并降低难治性缺血风险,而即刻有创治疗在降低大出血风险方面显示出益处。